Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

Breast Cancer Research and Treatment

Volumn 112, Issue 1, 2008, Pages 25-33

  Normanno, Nicola ^a   Campiglio, Manuela ^c   Maiello, Monica R ^a,b   De Luca, Antonella ^a,b   Mancino, Mario ^a   Gallo, Marianna ^a   D'Alessio, Amelia ^a   Menard, Sylvie ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Centro di Ricerche Oncologiche di Mercogliano CROM   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; Drug resistance; EGFR; MAPK; Tyrosine kinase inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CELL CLONE; CELL ISOLATION; CELL STRAIN; CELL STRAIN MDA MB 175; CELL STRAIN MDA MB 361; CELL STRAIN SK BR 3; CELL STRAIN ZD10; CELL STRAIN ZD6; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IMMUNOPRECIPITATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOPRECIPITATION; MITOGEN-ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 52949113842     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9830-2     Document Type: Article

References (35)

1. N Normanno C Bianco L Strizzi M Mancino MR Maiello A De Luca F Caponigro DS Salomon 2005 The ErbB receptors and their ligands in cancer: an overview Curr Drug Targets 6 243 257
2. V Shankar F Ciardiello N Kim R Derynck DS Liscia G Merlo BC Langton D Sheer R Callahan RH Bassin 1989 Transformation of an established mouse mammary epithelial cell line following transfection with a human transforming growth factor alpha cDNA Mol Carcinog 2 1 11
3. F Ciardiello ML McGeady N Kim F Basolo N Hynes BC Langton H Yokozaki T Saeki JW Elliott H Masui 1990 Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation Cell Growth Differ 1 407 420
4. R Brandt R Eisenbrandt F Leenders W Zschiesche B Binas C Juergensen F Theuring 2000 Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation Oncogene 19 2129 2137
5. DS Salomon R Brandt F Ciardiello N Normanno 1995 Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232
6. SL Moulder FM Yakes SK Muthuswamy R Bianco JF Simpson CL Arteaga 2001 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo Cancer Res 61 8887 8895
7. MM Moasser A Basso SD Averbuch N Rosen 2001 The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells Cancer Res 61 7184 7188
8. N Normanno M Campiglio LA De G Somenzi M Maiello F Ciardiello L Gianni DS Salomon S Menard 2002 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth Ann Oncol 13 65 72
9. J Anido P Matar J Albanell M Guzman F Rojo J Arribas S Averbuch J Baselga 2003 ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells Clin Cancer Res 9 1274 1283
10. M Campiglio A Locatelli C Olgiati N Normanno G Somenzi L Vigano M Fumagalli S Menard L Gianni 2004 Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level J Cell Physiol 198 259 268
11. N Normanno A De Luca MR Maiello M Mancino A D'Antonio M Macaluso F Caponigro A Giordano 2005 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development Front Biosci 10 2611 2617
12. A Agrawal E Gutteridge JM Gee RI Nicholson JF Robertson 2005 Overview of tyrosine kinase inhibitors in clinical breast cancer Endocr Relat Cancer 12 Suppl 1 S135 S144
13. A Polychronis HD Sinnett D Hadjiminas H Singhal JL Mansi D Shivapatham S Shousha J Jiang D Peston N Barrett D Vigushin K Morrison E Beresford S Ali MJ Slade RC Coombes 2005 Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial Lancet Oncol 6 383 391
14. IR Hutcheson JM Knowlden HE Jones RS Burmi RA McClelland D Barrow JM Gee RI Nicholson 2006 Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy Endocr Relat Cancer 13 Suppl 1 S89 S97
15. N Normanno MR Maiello M Mancino A De Luca 2004 Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview J Chemother 16 Suppl 4 36 40
16. R Bianco I Shin CA Ritter FM Yakes A Basso N Rosen J Tsurutani PA Dennis GB Mills CL Arteaga 2003 Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors Oncogene 22 2812 2822
17. QB She D Solit A Basso MM Moasser 2003 Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling Clin Cancer Res 9 4340 4346
18. HE Jones L Goddard JM Gee S Hiscox M Rubini D Barrow JM Knowlden S Williams AE Wakeling RI Nicholson 2004 Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells Endocr Relat Cancer 11 793 814
19. N Normanno A De Luca MR Maiello M Campiglio M Napolitano M Mancino A Carotenuto G Viglietto S Menard 2006 The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib J Cell Physiol 207 420 427
20. MR Maiello A D'Alessio A De Luca A Carotenuto AM Rachiglio M Napolitano L Cito A Guzzo N Normanno 2007 AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib Breast Cancer Res Treat 102 275 282
21. N Normanno C Bianco A De Luca MR Maiello DS Salomon 2003 Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment Endocr Relat Cancer 10 1 21
22. J Baselga J Albanell A Ruiz A Lluch P Gascon V Guillem S Gonzalez S Sauleda I Marimon JM Tabernero MT Koehler F Rojo 2005 Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer J Clin Oncol 23 5323 5333
23. KSER Albain WJ Gradishar DF Hayes E Rowinsky C Hudis L Pusztai D Tripathy S Modi S Rubi 2002 Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer Breast Cancer Res Treat 76 S33
24. NV Sergina M Rausch D Wang J Blair B Hann KM Shokat MM Moasser 2007 Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445 437 441
25. G von Minckwitz W Jonat P Fasching A du Bois U Kleeberg HJ Luck E Kettner J Hilfrich W Eiermann J Torode A Schneeweiss 2005 A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer Breast Cancer Res Treat 89 165 172
26. MJ Robinson SA Stippec E Goldsmith MA White MH Cobb 1998 A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation Curr Biol 8 1141 1150
27. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55
28. N Normanno A De Luca MR Maiello C Bianco M Mancino L Strizzi C Arra F Ciardiello S Agrawal DS Salomon 2004 CRIPTO-1: a novel target for therapeutic intervention in human carcinoma Int J Oncol 25 1013 1020
29. ML Janmaat FA Kruyt JA Rodriguez G Giaccone 2003 Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9 2316 2326
30. N Magne JL Fischel A Dubreuil P Formento MF Poupon P Laurent-Puig G Milano 2002 Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa") Br J Cancer 86 1518 1523
31. JM Knowlden IR Hutcheson HE Jones T Madden JM Gee ME Harper D Barrow AE Wakeling RI Nicholson 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 1032 1044
32. F Yamasaki MJ Johansen D Zhang S Krishnamurthy E Felix C Bartholomeusz RJ Aguilar K Kurisu GB Mills GN Hortobagyi NT Ueno 2007 Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt Cancer Res 67 5779 5788
33. W Xia S Bacus P Hegde I Husain J Strum L Liu G Paulazzo L Lyass P Trusk J Hill J Harris NL Spector 2006 A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer Proc Natl Acad Sci USA 103 7795 7800
34. JM Gee ME Harper IR Hutcheson TA Madden D Barrow JM Knowlden RA McClelland N Jordan AE Wakeling RI Nicholson 2003 The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro Endocrinology 144 5105 5117
35. IK Mellinghoff MY Wang I Vivanco DA Haas-Kogan S Zhu EQ Dia KV Lu K Yoshimoto JH Huang DJ Chute BL Riggs S Horvath LM Liau WK Cavenee PN Rao R Beroukhim TC Peck JC Lee WR Sellers D Stokoe M Prados TF Cloughesy CL Sawyers PS Mischel 2005 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors N Engl J Med 353 2012 2024